Intech Medical (01501.HK) to Acquire 23.18% Stake in DeJin Medical for Approximately USD 108 Million

INT Medical (01501) announced that on May 11, 2026, and May 12, 2026, the company entered into share transfer agreements with the sellers for the acquisition of a 23.18% stake in Valgen Holding Corporation at a total consideration of approximately US$108 million.

It is reported that the target company holds 100% equity of Valgen Medtech. The target company is a holding company without substantial business activities. Valgen Medtech mainly engages in the research, development, production, and sales of interventional treatment technologies and products for atrioventricular valve diseases (especially mitral and tricuspid valve interventions). Valgen Medtech is the main operating entity of the target group in China. Four self-developed products of the target group have been included in the special review process for innovative medical devices by the National Medical Products Administration, namely MitralStitch.^®Transapical Mitral Valve Repair System, DragonFly™ Transcatheter Mitral Valve Clip System, DragonFly-T^®Transcatheter Tricuspid Valve Clip System and DragonFire^®Transcatheter Radiofrequency Ablation System. Among them, the DragonFly™ Transcatheter Mitral Valve Clip System is the first domestically produced transcatheter mitral valve product approved by the National Medical Products Administration.

The Board believes that the acquisition provides the Company with an opportunity to complement its product pipeline in the field of structural heart disease, achieve more comprehensive product coverage in this area, and enhance the Group's overall competitiveness and long-term development potential in the cardiovascular intervention field.